<code id='651426BB0E'></code><style id='651426BB0E'></style>
      • <acronym id='651426BB0E'></acronym>
      <center id='651426BB0E'><center id='651426BB0E'><tfoot id='651426BB0E'></tfoot></center><abbr id='651426BB0E'><dir id='651426BB0E'><tfoot id='651426BB0E'></tfoot><noframes id='651426BB0E'>
      • <optgroup id='651426BB0E'><strike id='651426BB0E'><sup id='651426BB0E'></sup></strike><code id='651426BB0E'></code></optgroup>
        5. <b id='651426BB0E'><label id='651426BB0E'><select id='651426BB0E'><dt id='651426BB0E'><span id='651426BB0E'></span></dt></select></label></b><u id='651426BB0E'></u>
          <i id='651426BB0E'><strike id='651426BB0E'><tt id='651426BB0E'><pre id='651426BB0E'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-10-04 08:01:04 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：7731
                                  
                                    
          
                                   
          Alexis Borisy
          Venture capitalist Alexis Borisy																									Vanessa Leroy for STAT
          EQRx is done, sold for its cash.
          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
          advertisement
          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          The cancer drug shortage isn’t new — and neither are the solutions
                                
                            
          Next article：  
                                      
                                          How to save PrEP access — and even expand it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles